D-1065-2016 Class II Terminated
FDA drug recall D-1065-2016 was initiated by Allergan Sales, LLC on May 10, 2016 and is designated Class II. Reason for recall: Failed Content Uniformity Specifications. The recall status is terminated (terminated Dec 6, 2017).
Recall details
- Product Type
- Drugs
- Report Date
- Jul 13, 2016
- Initiation Date
- May 10, 2016
- Termination Date
- Dec 6, 2017
- Voluntary/Mandated
- Voluntary: Firm initiated
Product description
Tazorac (tazarotene) Gel 0.05%, 15 x 3.5g, sample packs, Allergan Inc, Irvine, CA 92612. UPC 300238335159
Reason for recall
Failed Content Uniformity Specifications.
Distribution pattern
Nationwide and Puerto Rico
Code information
Lot #: 84126, Exp FEB/2017
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1065-2016
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026